Iridex Corporation Receives European Patent on MicroPulse Technology
- Grant of the European Patent EP 3009093 for the Advanced Short Pulse Laser System
- Enhancement of safety and effectiveness of laser treatments for glaucoma and retinal diseases
- Addressing limitations of current technologies with controlled-width pulse trains
- Coverage of the full laser wavelength range from 520nm-615 nm
- Affirmation of Iridex's exclusive position as the only authorized provider of MicroPulse technology
- None.
Insights
The recent grant of the European Patent EP 3009093 to Iridex Corporation for its short pulse laser system signifies a strategic advancement in the field of ophthalmology. From an analytical standpoint, this patent solidifies Iridex's competitive edge by ensuring exclusivity in the European market for their MicroPulse technology. This is particularly relevant given the increasing prevalence of eye diseases such as glaucoma and retinal disorders, which necessitate innovative treatment methods.
The technology's ability to deliver controlled-width pulse trains with minimized thermal effects is a substantial improvement over traditional continuous wave lasers. This suggests potential for reduced complications and enhanced patient outcomes. For investors, this patent represents a barrier to entry for competitors and could translate into sustained revenue growth, especially if the technology is adopted as a standard of care.
However, it's important to consider the costs associated with the development and marketing of such advanced medical devices. The company will need to balance these costs against the potential increase in market share and pricing power afforded by the patent. Moreover, the long-term success will also depend on the adoption rate within the medical community and the ability to maintain the technological lead in a rapidly evolving industry.
The grant of a European Patent provides Iridex Corporation with a significant legal tool to protect its intellectual property in a highly competitive sector. The enforcement of this patent in both the Unified Patent Court member countries and the United Kingdom indicates a broad scope of protection for Iridex's proprietary technology. For stakeholders, this legal development is crucial as it can deter potential infringement by competitors, potentially reducing the risk of costly litigation.
Understanding the implications of this patent, one must also recognize the importance of the Unitary Patent system in Europe, which streamlines patent protection across multiple countries. This can lead to cost savings for Iridex in terms of both application and maintenance of patent rights across the continent, as opposed to navigating individual national patent laws.
However, the company must remain vigilant in monitoring and enforcing its patent rights, as the effectiveness of such protection is contingent upon the ability to detect and act against infringements. Additionally, the company should be prepared for the possibility of opposition proceedings, which can arise within the European patent system, potentially challenging the validity of the patent.
From a clinical perspective, the patented MicroPulse technology by Iridex represents a significant advancement in laser therapy for eye conditions. The ability to deliver short, controlled-width pulse trains can potentially reduce the risk of retinal damage, which is a common issue with existing laser treatments. This innovation could lead to more precise and safer procedures, improving patient care.
As an ophthalmologist, the introduction of this technology into the market could change treatment protocols for glaucoma and retinal diseases. The clinical benefits of minimizing full-thickness retinal damage could lead to a shift in preference towards Iridex's technology over traditional methods, assuming the clinical efficacy is validated by further studies and real-world use.
For the healthcare system and patients, the adoption of this technology could mean shorter recovery times and lower incidences of complications, which in turn could lead to cost savings. However, the initial costs of the technology and the training required for its adoption are factors that may affect its uptake. The long-term clinical data will be critical in determining the overall impact on patient care and healthcare economics.
The Advanced Short Pulse Laser System
MOUNTAIN VIEW, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the grant of the European Patent EP 3009093, entitled "Laser System with Short Pulse Characteristics and its Methods of Use”. This groundbreaking patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments. Iridex is the exclusive provider of MicroPulse® devices that utilize the patented technology.
Revolutionizing Eye Care with Precision and Safety The patented technology delivers a state-of-the-art laser system capability for delivering short, controlled-width pulse trains. This technology is designed to minimize the risk of full-thickness retinal damage and vision loss, a common concern with traditional laser treatments with numerous clinical studies demonstrating its safety and efficacy in retina and glaucoma applications and beyond. By employing a diode pump source and a frequency-doubled solid-state visible laser, the system produces a pulsed output with controlled thermal effects, focusing on tissue-specific photoactivation without photocoagulation damage.
Overcoming Limitations of Current Technologies This innovative MicroPulse technology addresses the limitations of current continuous wave visible lasers. It incorporates advanced software and hardware components in its feedback range control system, effectively managing energy fluctuations and enhancing safety during treatments. The system's ability to produce controlled-width pulse trains with reduced power fluctuations represents a novel leap forward in medical laser technology. This technology covers the full laser wavelength range from 520nm-615 nm. In European countries the Unitary Patent will be enforced by members of the Unified Patent Court as well as the United Kingdom.
A Commitment to Advancing Medical Laser Treatments "This advancement enhances both the safety and effectiveness of laser treatments in ophthalmology and the patent grant affirms our exclusive position as the only authorized provider of MicroPulse technology," stated David Bruce, President and CEO of Iridex Corporation.
About Iridex Corporation Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical expectations and commercial trends, market adoption and expansion, demand for and utilization of the Company's products and results and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 20, 2023. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Media Contact
Steven Koufos
skoufos@iridex.com
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
END
Note: The information in this press release is based on the EP 3009093 A1 patent by Iridex Corporation. For a detailed view of the patent, please visit European Patent Office.
FAQ
What is the ticker symbol for Iridex Corporation?
What is the European Patent EP 3009093 about?
What does the patented technology of Iridex Corporation address?
What is the wavelength range covered by the technology?
Where will the Unitary Patent be enforced?
Who is the President and CEO of Iridex Corporation?
